Important Information
If you are interested in applying for this study, please:
- Read the study description.
- Review the Visit Planner dates in your location and confirm that you are available for the stated dates.
- Complete the registration form below.
We will then contact you to check your suitability and share the Participant Informed Consent Form for you to read.
Study Description
New Zealand Clinical Research is trialling an investigational medicine that could help people with obesity.
Worldwide, obesity and type 2 diabetes effects approximately 12% of adults. This rate continues to grow every year. The two conditions are closely linked and can lead to serious consequences and an array of metabolic, cardiovascular, and other conditions. This impacts the health-associated quality of life and is of significant cost for healthcare systems around the world. Lifestyle modification, including diet, exercise, and behavioural change, remain key in the initial management of obesity. Any weight loss achieved with lifestyle interventions alone is challenging to maintain.
The study medicine, ARO-ALK7, is being investigated to see if it can help people with obesity by targeting the liver cells to reduce Activin E protein levels. This protein is involved in the regulation of fat (lipid) storage and breakdown of fat in the tissue (lipolysis). It is hoped that ARO-ALK7 may reduce fat storage and improve fat breakdown in the body and improve blood sugar levels in people with obesity. Utilising a combination treatment approach with GLP-1 drugs, ARO-ALK7 is being evaluated to determine whether it can provide an improved side effect profile and better health outcome for people affected by this condition.
This is an investigational medicine because it has not been approved by MedSafe or other drug regulatory authorities.
This study (2024 FULL 21748) is being funded by Arrowhead Pharmaceuticals, Inc and has been approved by the Health and Disability Ethics Committee.
Requirements
Healthy Males and Females
- Aged between 18 – 65 years
- Weigh up to 150 kgs
- BMI (Body Mass Index) between 30 – 50 kg/m²
- Non-smokers/vapers or Ex-smokers/vapers allowed
- Some medications allowed
- Have at least one unsuccessful attempt to lose weight via lifestyle changes (e.g. reduced calorie diets, increasing exercise, etc.)
What is Involved?
Study Visits:
Part 1B MAD: 1 x 2-night stay + 1 x 1-night stay (for a total of 3-nights) + 15 clinic visits
Reimbursement:
Part 1B MAD: Up to $8,300 before tax